SP
IONS icon

Symmetry Partners’s Ionis Pharmaceuticals IONS Stock Holding History

Symmetry Partners’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-4,718
Closed -$303K – 357
2019
Q2 		$303K Buy
4,718
+3,983
+542% +$282K 0.06% 246
2019
Q1 		$60K Buy
+735
New +$47.4K 0.01% 409

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Symmetry Partners's IONS Position: Q3 2019 in Review

Symmetry Partners sold out of Ionis Pharmaceuticals (IONS) in Q3 2019, closing a stake of 4,718 shares — an estimated $303K sold.

Symmetry Partners first reported a position in IONS in Q1 2019 and held it in 2 quarters. The position peaked at $303K in Q2 2019. 369 funds tracked by Wall St. Rank hold IONS as of Q3 2019.

  • Symmetry Partners reported no remaining Ionis Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
  • Symmetry Partners sold 4,718 Ionis Pharmaceuticals shares in Q3 2019, an estimated $303K.
  • Symmetry Partners first reported a position in Ionis Pharmaceuticals in Q1 2019 and held it in 2 quarters.
  • Symmetry Partners's Ionis Pharmaceuticals position peaked at $303K in Q2 2019.
  • 369 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q3 2019.

Based on Symmetry Partners's 13F filing for Q3 2019, filed 4 Nov 2019.